# Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD

> **NCT01958593** · PHASE2 · TERMINATED · sponsor: **Resilient Pharmaceuticals** · enrollment: 6 (actual)

## Conditions studied

- Posttraumatic Stress Disorder

## Interventions

- **DRUG:** Placebo
- **DRUG:** Midomafetamine HCl
- **BEHAVIORAL:** Psychotherapy

## Key facts

- **NCT ID:** NCT01958593
- **Lead sponsor:** Resilient Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10-14
- **Primary completion:** 2015-09-10
- **Final completion:** 2016-10-17
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** This pilot study was terminated early by sponsor due to insufficient rate of accrual.
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01958593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01958593, "Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01958593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*